Takeda Immuno-Oncology Call for Proposals 2020
Takeda is a global, value-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda Oncology is currently moving a broad portfolio of innovative internal and external Immuno-Oncology assets into the clinic and are looking for to expand our research efforts on novel target identification and validation.
- Short proposal submission due August 14th (EXTENDED to August 28th)
- Notification of selected Short proposals October 2nd
- Full proposal submission due October 30th
- Announcement of awards Mid November
For More Information, Please Contact:
Office of Technology Licensing
Stanford School of Medicine - The Catalyst COVID RFA
The Catalyst COVID RFA is a funded effort supported by the leadership of Stanford Medicine to identify and implement COVID-inspired innovations coming from within the Stanford community.
We are seeking innovations based on our experiences with the COVID-19 pandemic, that can have a positive impact on patients, physicians, healthcare operations, and future societal readiness for population-scale issues. The emphasis of this RFA is on rapid clinical implementation of transformative innovations.
The goals of the program are to:
- Identify new Stanford Community innovations inspired by COVID-19, and that can have a lasting effect for the long-term.
- Implement, perfect, and scale innovations for maximum impact
- If appropriate, export innovations through commercialization or open-source distribution
Who Can Apply: Anyone at Stanford, including all faculty, staff, and students with ready-to-implement innovative solutions to the challenges facing our patients and health system.
Extended Application Deadline: August 3rd (midnight)
What Should Applicants Expect: our team will review submissions to the RFA and invite Stanford faculty, staff and investment community members to score and rate ideas based on a number of factors including impact to healthcare, marketability, novelty, and differentiation for Stanford.
The following resources may be allocated to submissions with the highest score:
- Funding from $25K to $500K per innovation (budget justification required)
- Implementation and strategic support
- Business planning and market assessment
- Regulatory and internal operations navigation
Example ideal submissions might include innovations that solve for better digital solutions for distance healthcare (e.g. remote monitoring and telehealth), enhanced personal protection equipment for patients and staff, or inexpensive, rapid testing solutions, to name a few.
SAMSUNG Global Research Outreach (GRO) Program
Institutional representative (RPM/RMG or OSR) deadline: August 18, 2020
Full proposal deadline: August 25, 2020, 5pm PST via GRO online submission website
• Stanford faculty with PI eligibility may apply to this program.
• This is a research grant, and per Stanford PIship policy, only faculty with PI eligibility may apply.
• Find the research themes below (sub-themes are available for download on the GRO website).
Amount of funding:
• Funding amounts typically range from $100K to $200K overall (direct and indirect costs) for one year.
• Download the PDF file of the specific research sub-theme to view the amount of funding per year (scroll to the bottom of the webpage).
• Stanford’s Industrial Contract Office (ICO) in the Office of Technology and Licensing (OTL)* has have confirmed that Samsung will provide full indirect cost reimbursement (which is in compliance with Stanford’s policy).
The SAMSUNG Global Research Outreach (GRO) Program is an important part of growing SAMSUNG Electronics's academic research engagement and collaboration platforms. World-class university researchers have been annually invited since 2009 to propose novel research ideas and to work with our R&D teams to foster technological innovation. This has resulted in actively collaborative relationships with over 150 leading universities worldwide. Selected GRO projects will be funded with one year. This project may be extended up to three years, based on annual research outcomes and necessity for further research partnership determined by SAMSUNG. Joint research proposals from multiple universities are welcome and acceptable. The GRO Program represents an opportunity for SAMSUNG and universities to build a mutually beneficial research relationship and we look forward to your participation. SAMSUNG does not require, and does not desire, to receive any information that may be deemed confidential by the university researcher or the university.
The 2020 GRO Program is seeking novel ideas in the following research themes:
• Ultralow-power Cryogenic Computing
• Metaphotonics for Next Information & Communication Technologies (ICT)
• Next generation DRAM/NAND
• Functional Oxide
• New Quantum Dot
• New Light Sensitive Materials
• Privacy Preserving Computing
• Machine Intelligence
• 6G communication systems
• Fundamental technology for semiconductor equipment
• Bulk Acoustic Wave
Questions? Please contact firstname.lastname@example.org or Lisa Chen in the Industrial Contracts Office (ICO-OTL)
Semiconductor Research Corporation (SRC)
SRC is soliciting white papers in the areas of:
- AI Hardware (AIHW) – Opens May 27, 2020
- Analog/Mixed-Signal Circuits, Systems, and Devices (AMS-CSD) – Opens June 1, 2020
- Logic and Memory Devices (LMD) – Opens June 1, 2020
- Nanomanufacturing Materials and Processes (NMP) – Opens June 1, 2020
- Environment, Safety, and Health (ESH) – Opens June 1, 2020
Please note white papers addressing the needs in the corresponding Research Needs documents are to be uploaded by the deadline noted in each solicitation timeline. Each researcher may be involved in no more than two submissions per call. A selected white paper will result in an invitation to submit a full proposal for further consideration for a research contract.
Sanofi Innovation Awards (iAwards)
Internal deadline: June 8, 2020
Limited funding opportunity for faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver) involved in multi-therapeutic areas including: immuno-oncology, molecular oncology, and immunology & inflammation. Priority will be given to early stage therapeutics, novel disease targets, mechanisms and screening assays, new disease relevant animal models, biomarkers and technologies that improve drug discovery and development. A university-wide internal selection process is required.